Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium “Long-Acting Injectables” Working Group
Andrea Bauer(Sunovion (United States)), Stephanie E. Barrett(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christopher D. Morrison(Pennington Biomedical Research Center), Venkat R. Koganti(Bristol-Myers Squibb (Germany)), Shweta Urva(Eli Lilly (United States)), Sudhir S. Chakravarthi(The Bristol-Myers Squibb Children's Hospital), Ashish Garg(Max Super Speciality Hospital), Maxime Siemons(Janssen (Belgium)), Philippe Berben(UCB Pharma (Belgium)), Yi Shi(Center for Life Sciences), Pratik Saha(GlaxoSmithKline (United States)), Ramesh Palaparthy(Gilead Sciences (United States)), Sayantan Chattorraj(GlaxoSmithKline (United States)), Sara Shum(Io Therapeutics (United States)), Ryan Vargo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tycho Heimbach(Merck & Co., Inc., Rahway, NJ, USA (United States)), Naveen K. Thakral(Analytical Services), Betty Gourdon(Biogen (United States)), Ye Huang(AbbVie (United States)), Deepak Mundhra(GlaxoSmithKline (United States)), Abdul Naveed Shaik(Gilead Sciences (United States))
Cited by 64
Related Papers
Defining the Nutritional and Metabolic Context of FGF21 Using the Geometric Framework
|Cell Metabolism|2016|214
Self-assembly and applications of biomimetic and bioactive peptide-amphiphiles
|Soft Matter|2006|185
Short Chain Fatty Acids: Fundamental mediators of the gut-lung axis and their involvement in pulmonary diseases
|Chemico-Biological Interactions|2022|151
Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide
|International Journal of Pharmaceutics|2008|148
Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
|Advances in Cancer Biology - Metastasis|2024|134